/

ENTA

Enanta Pharmaceuticals, Inc.Closed

11.52−0.78 −6.34%USD

NasdaqGS · as of Oct 13, 16:00 ET · 15m delayAfter hours 11.52 0.00%

Open

12.37

Prev close

12.30

Day range

11.3912.37

52-week range

10.2017.15

Volume

173.99K0.76×

Mkt cap

335.52M

P/E ttm

—

Fwd P/E

-4.85

EPS ttm

-2.42

Div yield

0.00%

Earnings

—

From 52w high

−32.83%

Price Chart

Yahoo Finance · delayed

ENTAOct 13, 2026O 12.37H 12.37L 11.39C 11.52−0.78 (−6.34%)Vol 174.00K

SMA 5013.03
SMA 20013.39

1Y change +4.54% since Oct 10, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

ENTA Enanta Pharmaceuticals, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −5.34%
1 month: −11.11%
3 months: −12.13%
6 months: −21.26%
Year to date: −26.95%
1 year: +0.26%

Valuation & ownership

Market cap: 335.52M
Enterprise value: 328.06M
P/E (ttm): —
Forward P/E: -4.85
PEG ratio: —
Price / book: 3.32
Price / sales (ttm): 5.14
EV / EBITDA: -6.10
EPS (ttm): -2.42
EPS (forward): -2.37
Beta (5y monthly): 0.96
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 29.13M
Float: 22.52M
Short % of float: 10.49%
Short ratio (days): 9.63
Held by insiders: 4.67%
Held by institutions: 94.39%
Avg volume (3m): 229.69K
50-day average: 13.06
200-day average: 13.41
52-week change: +0.26%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 37.9
vs 50-day SMA: −11.58%
vs 200-day SMA: −13.94%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 5.31%
Realised vol (20d, ann.): 49.6%
From 52-week high: −32.83%
From 52-week low: +12.94%

ANR

Analyst Consensus

6 analysts

Consensus

—

Mean target

21.83

+89.53% implied

Low 19.00Median 20.00High 32.00

Recommendation trend

Now6 / 0 / 0
1m ago6 / 0 / 0

DES

About Enanta Pharmaceuticals, Inc.

Yahoo Finance profile

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Sector: Healthcare
Industry: Biotechnology
Employees: 120
Headquarters: Watertown, MA, United States
Website: enanta.com
Officers: Dr. Jay R. Luly Ph.D. President, CEO & Director
Dr. Yat Sun Or Ph.D. Chief Scientific Officer
Dr. Scott T. Rottinghaus M.D. Chief Medical Officer

SEAS

Seasonality · ENTA

2013–2026 · monthly returns

Strongest month Nov +7.75%Weakest month May −5.24%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-18.2	10.9	-11.7	10.0	-5.3	10.8	-13.6	5.8	-1.1	-12.6			−26.9%
2025	-11.1	52.3	-29.0	10.3	-2.6	27.5	0.3	10.8	42.5	-8.4	28.8	11.7	+174.3%
2024	29.1	18.3	21.5	-21.3	-9.2	4.0	13.8	-12.7	-19.6	8.5	-23.5	-33.1	−38.9%
2023	14.7	-9.1	-16.6	-12.1	-34.0	-8.9	-11.4	-21.7	-24.8	-19.2	3.5	0.7	−79.8%
2022	-20.5	18.5	1.1	-9.5	-38.0	18.4	16.7	10.4	-14.8	-13.0	-2.9	6.2	−37.8%
2021	14.2	2.6	0.0	2.9	-4.1	-9.6	-4.0	35.4	-0.7	51.1	2.8	-15.3	+77.6%
2020	-16.6	-1.3	1.1	-9.8	11.0	-2.5	-8.7	13.8	-12.3	-4.7	-5.6	2.2	−31.9%
2019	12.1	29.1	-6.8	-8.7	3.8	-6.7	-11.1	-6.0	-14.8	1.3	4.6	-3.0	−12.8%
2018	44.8	-7.5	2.9	15.0	7.2	16.1	-15.9	-6.8	-6.0	-9.7	2.6	-10.5	+20.7%
2017	-1.1	-13.0	6.9	3.1	-5.3	19.6	5.9	12.5	9.2	6.1	-0.0	18.2	+75.2%
2016	-22.2	10.5	3.5	-0.6	-16.0	-10.1	2.0	-2.2	21.0	-11.6	33.7	6.6	+1.5%
2015	-14.6	-17.5	-14.5	11.8	19.4	10.1	12.6	-22.9	-7.4	-22.3	12.1	4.8	−35.1%
2014	34.1	0.7	8.6	-7.0	2.1	13.4	-12.7	11.6	-5.7	8.7	9.2	8.3	+86.4%
2013				9.7	-2.4	-9.1	3.6	1.3	23.4	-12.9	35.4	0.9	+49.9%

INSD

Insider Activity · ENTA

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Feb 11, 2026	Luly Jay RChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	20K	—
Feb 11, 2026	Or Yat SunOfficer	Stock Award(Grant) at price 0.00 per share.	6.9K	—
Feb 11, 2026	Kowalsky Matthew PaulOfficer	Stock Award(Grant) at price 0.00 per share.	5.5K	—
Feb 11, 2026	Kieffer Tara LynnOfficer	Stock Award(Grant) at price 0.00 per share.	6.6K	—
Feb 11, 2026	Luu BrendanOfficer	Stock Award(Grant) at price 0.00 per share.	6.6K	—
Feb 11, 2026	Rottinghaus Scott T.Officer	Stock Award(Grant) at price 0.00 per share.	6.9K	—
Dec 4, 2025	Or Yat SunOfficer	Sale at price 14.23 per share.	2.4K	$34.01K
Dec 4, 2025	Kieffer Tara LynnOfficer	Sale at price 14.23 per share.	2.1K	$29.97K
Dec 4, 2025	Luu BrendanOfficer	Sale at price 14.23 per share.	1.4K	$19.84K
Dec 4, 2025	Rottinghaus Scott T.Officer	Sale at price 14.23 per share.	798	$11.36K
Dec 4, 2025	Capps Kathleen S. CpaOfficer	Sale at price 14.23 per share.	323	$4.60K
Dec 4, 2025	Luly Jay RChief Executive Officer	Sale at price 14.23 per share.	4.7K	$67.49K
Dec 4, 2025	Trout Harry R IiiOfficer	Sale at price 14.23 per share.	542	$7.71K
Dec 1, 2025	Capps Kathleen S. CpaOfficer	Sale at price 13.96 per share.	207	$2.89K
Dec 1, 2025	Trout Harry R IiiOfficer	Sale at price 13.96 per share.	380	$5.30K
Nov 24, 2025	Trout Harry R IiiOfficer	Stock Award(Grant) at price 0.00 per share.	6.5K	—
Nov 24, 2025	Capps Kathleen S. CpaOfficer	Stock Award(Grant) at price 0.00 per share.	3.2K	—
Feb 11, 2025	Mellett Paul J JrOfficer	Stock Award(Grant) at price 0.00 per share.	7.5K	—
Feb 11, 2025	Luly Jay RChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	25.5K	—
Feb 11, 2025	Or Yat SunOfficer	Stock Award(Grant) at price 0.00 per share.	9.8K	—

13F

Investors Holding ENTA

latest 13F filings of 29 followed managers

Investors holding ENTA
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$8.1M	0.01%	557.60K	−16%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

ENTA

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

ENTA

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Enanta Pharmaceuticals, Inc.

Seasonality · ENTA

Insider Activity · ENTA

Congress Trades · ENTA

Investors Holding ENTA

Investors Holding ENTA

Congress Trades · ENTA

Insider Activity · ENTA

Seasonality · ENTA

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Enanta Pharmaceuticals, Inc.

Financial Snapshot

Earnings & Dividends

News